BUCHANAN INGERSOLL & ROONEY PC lobbying for GENERIC ANIMAL DRUG ALLIANCE

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 22, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Maryland

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 1683
Generic Animal Drug Advancement Act
HR 1418
Animal Drug and Animal Generic Drug User Fee Amendments of 2023

Lobbying activity 4

Medical/Disease Research/Clinical Labs

Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions

Animals

Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions

Health Issues

Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions

Pharmacy

Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions